Compare American Well Corp (AMWL) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Well Corp vs Regeneron Pharmaceuticals Inc — how do they compare? American Well Corp trades at $13.01 (market cap $230.98M), while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 360.2× American Well Corp's market cap, and Regeneron Pharmaceuticals Inc pays a 0.47% dividend while American Well Corp pays none. Which is the better fit depends on your goals.
| AMWL | REGN | |
|---|---|---|
Market Cap | $230.98M | $83.19B |
Sector | Health | Health |
52-Week High | $13.58 | $812.27 |
52-Week Low | $3.78 | $555.51 |
Enterprise Value | $38.01M | $77.90B |
Dividend Yield | — | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMWL (American Well Corporation) trades at $13.52, up 4.56% today, with a bullish technical signal from moving averages. The company shows improving financial trends with narrowing losses—net income margin improved from -97.57% in 2022 to -35.75% in 2026—and positive earnings beats in recent quarters. Recent news highlights include a Defense Health Agency partnership intent and leadership changes at Amazon's healthcare unit involving an Amwell co-founder. Operating cash flow losses have decreased significantly from -$192M in 2022 to -$26M projected for 2026.
Outlook: AMWL's path to operating breakeven by Q4 2026 and reduced cash burn present a turnaround opportunity, but persistent revenue declines and negative margins pose risks. Analyst sentiment is mixed with 33% buy ratings. The stock's valuation at P/S of 1.02 appears reasonable if growth resumes, but execution on profitability targets is critical for sustained upside.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Well Corp
American Well Corp is a telehealth company enabling digital delivery of care for its customers. Its platform, Amwell, digital care delivery solution that equips health systems, health plans, government, and innovator clients with the tools to enable new models of care for their patients and members enabling care delivery across the full healthcare continuum - from primary and urgent care in the home to high acuity specialty consults, such as telestroke and telepsychiatry, in the hospital. It provides both on-demand and scheduled consultations. Its Health Plan Programs include Virtual Primary Care, Musculoskeletal Care, Dermatology Care, and Chronic Care among others and its Health System Modules include Acute Behavioral Health, ED Triage, Pediatrics and Telestroke among others.
Read more on AMWL →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
